Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pancreatic Cancer Metastatic × Gemcitabine × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 68 Carcinoma, Non-Small-Cell Lung 57 Breast Neoplasms 32 Nasopharyngeal Carcinoma 26 Lung Neoplasms 26 Urinary Bladder Neoplasms 23 Ovarian Neoplasms 18 Neoplasm Metastasis 17 Cholangiocarcinoma 15 Triple Negative Breast Neoplasms 13 Lymphoma, Large B-Cell, Diffuse 13 Uterine Cervical Neoplasms 12 Gallbladder Neoplasms 12 Biliary Tract Neoplasms 12 Recurrence 11 Neoplasms 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Carcinoma, Transitional Cell 10 Non-Muscle Invasive Bladder Neoplasms 9 Nasopharyngeal Neoplasms 8 Lymphoma 7 Fallopian Tube Neoplasms 7 Carcinoma 7 Bile Duct Neoplasms 7 Lymphoma, Non-Hodgkin 6 Carcinoma, Hepatocellular 5 Adenocarcinoma 5 Urothelial Cancer 3 Neoplasms by Site 3 Lymphoma, T-Cell, Peripheral 3

Interventions

folfirinox 1 devimistat 1 Paclitaxel 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Injections 1 Gemcitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06752811 2026-02-10

pompom

Shanghai Yizhong Pharmaceutical Co., Ltd.

Phase 3 Recruiting

Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡